RANBAXY

Ranbaxy Laboratories Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 09, 2012, have approved the appointment of Dr. Kazunori Hirokawa, as an Additional Director. Dr. Hirokawa, M. D. Ph.D, is a member of the Board, Senior Executive Officer and Head of Corporate Strategy Division of Daiichi Sankyo Company, Limited, Japan.

Ranbaxy Laboratories Limited has informed the Exchange that Mr. Indrajit Banerjee has joined as President & Chief Financial Officer of the Company on August 24, 2011. Mr. Banerjee is a Chartered Accountant and brings with him around 32 years of rich experience with the Organisations like PricewaterhouseCoopers (PWC), Indian Aluminium Company Limited, Lucent Technology, Lupin India Limited and Cairn India Limited.

Ranbaxy Laboratories Ltd has informed the Exchange that in the Board meeting of the Company held on May 24, 2009: a) Mr. Malvinder Mohan Singh stepped down as Chairman, CEO & Managing Director of the Company with immediate effect; and b) Mr. Sunil Godhwani, Mr. Balinder Singh Dhillon and Mr. Atul Sobti resigned from the Directorship of the Company with immediate effect. At the subsequent Board meeting held on May 24, 2009: a) Dr. Tsutomu Une, Non-Executive Director was elected as the Chairman of the Board of Directors of the Company; and b) Mr. Atul Sobti was appointed as CEO & Managing Direct

Ranbaxy Laboratories Ltd has informed the Exchange that the Board at its meeting held on March 27, 2009 has approved the following: "(1) Appointment of Mr. Percy Shroff as a Director (Independent) of the Company in the casual vacancy caused by the resignation of Mr. Harpal Singh. Mr. Shroff has over 20 years experience in the medical field in Japan and India. He established the India offices and business operations for the Swedish multinational Elekta AB.. Mr. Shroff is Managing Director - India Head of Elekta Medical Systems India Pvt. Ltd., Gurgaon which is in the business of sales, servicin

Ranbaxy Laboratories Ltd has informed the Exchange regarding outcome of the meeting of Board of Directors of the Company held on December 19, 2008. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_appointmentresig_19122008.ZIP target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that Mr. Surendra Daulet-Singh has resigned from the directorship of the Company with effect from December 15, 2008.

Ranbaxy Laboratories Ltd has informed the Exchange that "Dr. Brain W. Tempest, Chief Mentor and Executive Vice Chairman of the Board of Directors of the Company has retired from the services of the Company effective close of business hours on December 31, 2007 on completion of his term".

Ranbaxy Laboratories Ltd has informed the Exchange that: "Mr. Sunil Godhwani was appointed as a Director of the Company in the casual vacancy caused by resignation of Mr. Tejendra Khanna who would have otherwise held office of Director upto the Annual General Meeting (AGM) i.e. May 31, 2007. Accordingly, Mr. Godhwani's term as a Director in the aforesaid casual vacancy ended on the conclusion of the AGM held today i.e. May 31, 2007. Subsequent to the AGM, the Board at its meeting held on May 31, 2007 appointed Mr. Sunil Godhwani as an Additional Director of the Company".

Ranbaxy Laboratories Ltd has informed the Exchange that "The Board of Directors at its meeting held today i.e. April 27, 2007 has : (1) Elected Mr. Harpal Singh as Non - Executive Chairman of the Board of Directors. He has been a Director on the Board since July, 2000; and (2) Appointed Mr. Sunil Godhwani as a Director of the Company in the casual vacancy caused by the resignation of Mr. Tejendra Khanna. Mr. Godhwani is the CEO & Managing Director of Religare Enterprises Limited and Managing Director of Fortis Financial Services Ltd. He is aged about 46 years with over twenty years of working

Ranbaxy Laboratories Ltd has informed the Exchange that " the appointment of Shri Tejendra Khanna as Lt. Governor of Delhi, he has resigned from the Directorship of Ranbaxy Laboratories Limited effective April 08, 2007".

Ranbaxy Laboratories Ltd has informed the Exchange that the Board of Directors at its meeting held on July 28, 2005 has approved the appointment of Mr. Ravi Mehrotra as an Additional Director on the Board of Directors of the Company w.e.f. July 28, 2005, Mr. Mehrotra is the President for Franklin Templeton Asset Management (India) Pvt. Ltd.

Ranbaxy Laboratories Ltd has informed the Exchange that the BODs at its meeting held on January 18,2005, has approved the appointment of Mr. Ramesh L Adige-Vice President(Corporate Affairs) as Whole-time Director of the Company effective January 18,2005.